Global Allogeneic CAR-T Cell Patent Landscape Report and Forecast 2024-2032

The global allogenic CAR-T cell market was valued at USD 8.4 billion in 2023, driven by extensive patent filings in technological innovations in gene editing. The market is expected to grow at a CAGR of 29.8% during the forecast period of 2024-2032, reaching a market value of USD 88.3 billion by 2032. The patent landscape is influenced by enhancing treatment protocols, improving manufacturing processes, and developing strategies to overcome immune rejection, reflecting the sector's robust innovation and development.

Patent Landscape Report Coverage

The global allogenic car-t cell patent landscape report offers an in-depth analysis of the current and future patent environment for allogenic CAR-T cells. It covers key drivers, including advancements in gene editing technologies such as CRISPR and TALEN, enhanced manufacturing processes, and strategies to overcome immune rejection. The report segments patents by target indications like Acute Lymphoblastic Leukaemia and target antigens like CD19, highlighting notable innovations and their potential to drive industry growth. Additionally, it provides a jurisdictional analysis of patent activities in the United States, Europe, and Asia Pacific, along with profiles of key companies actively filing patents in this sector.

Global Allogenic CAR-T Cell Patent Outlook

• Several regions are actively involved in the patent landscape for allogenic CAR-T cells across the globe. The United States leads the field, reflecting its strong biopharmaceutical sector and continuous innovation. Europe, particularly Germany, the United Kingdom, and France, has a significant number of patents, focusing on enhancing treatment protocols and manufacturing processes. The Asia Pacific region, especially China and Japan, is emerging as a key player with numerous patents. These regions are poised to dominate the patent landscape in the future, driven by advancements in gene editing, CAR constructs, and scalable manufacturing processes.
• The allogenic CAR-T cell patent landscape involves numerous biotech firms and academic institutions. These entities are driving innovation through extensive patent filings that cover new CAR constructs, advanced gene editing techniques, enhanced manufacturing processes, and strategies to overcome immune rejection. The collective effort of these organisations is crucial for advancing allogenic CAR-T cell therapies.
• In the United States, patents are predominantly focused on innovative CAR constructs and gene editing technologies, reflecting the country's robust research infrastructure. European patents often emphasise manufacturing processes and quality control measures, aligning with the region's stringent regulatory standards. In the Asia Pacific, patents are increasingly addressing scalable production methods and cost-effective solutions, reflecting the region's dynamic and expanding biopharmaceutical landscape. These jurisdictional trends highlight the diverse focus areas and strengths of each region in the allogenic CAR-T cell patent landscape.

Allogenic CAR-T Cells: Introduction

Allogenic CAR-T cells, derived from healthy donors, represent a revolutionary approach in cancer immunotherapy, offering the potential for off-the-shelf treatments. Unlike autologous CAR-T cells, which are personalised from the patient's own cells, allogenic CAR-T cells provide a scalable and more accessible option for cancer patients worldwide. This innovative therapy is increasingly reflected in the global patent landscape, highlighting its growing significance and potential.

• Advancements in gene editing technologies, such as CRISPR and TALEN, are driving the patent landscape for allogenic CAR-T cells. Patents are being filed for novel gene editing methods and tools that enhance the safety and precision of CAR-T cells. These patents focus on minimising off-target effects and improving gene insertion accuracy, crucial for developing effective allogenic CAR-T therapies.
• Patents focused on improving the manufacturing processes of allogenic CAR-T cells are crucial for scalability and cost reduction. These patents cover new bioprocessing techniques and scalable production methods that standardise cell production, reduce contamination risks, and ensure consistent quality across large batches. Such innovations are essential for making these therapies commercially viable and widely available.
• The patent landscape is also driven by innovations aimed at overcoming immune rejection in allogenic CAR-T therapies. Patents in this area include methods for immune modulation and engineering CAR-T cells to evade detection by the recipient's immune system. These patents often involve modifying antigen expression and incorporating immune-suppressive agents, ensuring that allogenic CAR-T cells can persist and function effectively within the patient without being attacked by their immune system.

These drivers collectively shape a vibrant and swiftly advancing patent landscape in the allogenic CAR-T cell sector, heralding substantial innovations and broader utilisation in the coming years.

Global Allogenic CAR-T Cell Patent Segmentation Analysis

The report provides an in-depth analysis of the patents in this field by the following segmentation :

Analysis by Target Indication

• Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Others

The patent segments in the allogenic CAR-T cell industry by target indication, specifically Acute Lymphoblastic Leukaemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, and Mantle Cell Lymphoma, demonstrate notable advancements. Acute Lymphoblastic Leukaemia dominates the patent landscape due to its significant industry focus. These patents drive innovation in CAR constructs and treatment protocols, enhancing therapy efficacy and safety. Such advancements are poised to drive future growth, cementing their role in improving patient outcomes and broadening the applicability of allogenic CAR-T cell therapies, thus propelling the field forward in the forecast period.

Analysis by Target Antigens

• CD19
• BCMA
• CD20
• CD19/22
• Others

The patent segments in the allogenic CAR-T cell industry by target antigens, specifically CD19, BCMA, CD20, and CD19/22, demonstrate notable advancements. CD19 dominates the patent landscape due to its significant therapeutic potential. These patents drive innovation in targeting these specific antigens, enhancing the efficacy and precision of therapies. Such advancements are poised to drive future growth, cementing their role in improving treatment outcomes and broadening the applicability of allogenic CAR-T cell therapies. This progress propels the field forward, making these antigens essential targets in the forecast period.

Allogenic CAR-T Cell Patent Jurisdiction Analysis

The global landscape for allogenic CAR-T cell patents is rapidly evolving, with significant activity across key regions including the United States, Europe, and Asia Pacific. Each jurisdiction shows unique trends in patent filings and company involvement, reflecting regional interests and advancements in this innovative field.

In the United States, over 300 patents have been filed for allogenic CAR-T cells. Major pharmaceutical companies are leading the filings, highlighting strong interest and investment in this sector. The trend suggests continued robust patent activity as more companies enter the field.
In the Asia Pacific region, particularly in China and Japan, over 150 patents have been filed for allogenic CAR-T cells. Both local and international companies are showing increasing interest, with a growing number of patent applications expected in the coming years. This reflects the region’s dynamic and expanding biopharmaceutical landscape.

Patent Profile of Key Companies

The patent landscape for allogenic CAR-T cells is shaped by several key companies driving innovation and securing intellectual property. Here is an overview of their patent activities.

Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Inc., established in 2019 and headquartered in San Diego, California, is actively involved in multiple patents focused on combining natural killer (NK) cell therapies with CAR technology to enhance the efficacy and scalability of allogenic CAR-T cells. The company's strategic patent filings aim to position Artiva as a leader in innovative cancer treatments.

Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., founded in 2014 and also based in San Diego, has a robust patent portfolio leveraging its proprietary gene editing technologies, including the piggyBac DNA Modification System. Poseida has secured several patents to improve the safety, durability, and efficacy of allogenic CAR-T cells, with ongoing efforts to expand its intellectual property in this field.

Nanjing Beiheng Biological Technology Co., Ltd.
Nanjing Beiheng Biological Technology Co., Ltd., established in 2015 and headquartered in Nanjing, China, is an emerging player in the allogenic CAR-T cell patent landscape. The company focuses on developing innovative patents to advance the development of allogenic CAR-T cells, contributing to the growing field of immunotherapy.

Other key players in the industry include NantCell, Inc., GC Cell Corp.

Key Questions Answered in the Global Allogenic CAR-T Cell Patent Landscape Report

• Which technological advancements are driving patent filings in the allogenic CAR-T cell sector?
• How are improvements in manufacturing processes influencing patent activities?
• What strategies are being patented to overcome immune rejection in allogenic CAR-T cells?
• Which target indications are the focus of current allogenic CAR-T cell patents?
• What role do target antigens such as CD19 and BCMA play in the patent landscape?
• How does the patent activity differ across key regions like the United States, Europe, and Asia Pacific?
• Which companies are leading in the number of patents filed for allogenic CAR-T cells?
• What future opportunities exist for patent development in the allogenic CAR-T cell landscape?
• How are collaborative efforts and licensing agreements shaping the patent landscape?
• What are the current unmet needs and challenges in the landscape?
• What are the key challenges faced in the patenting process for allogenic CAR-T cell technologies?
• What are the recent breakthroughs in gene editing that have influenced patent trends in allogenic CAR-T cells?
• How are patient outcomes and clinical trial results influencing patent filings in this sector?
• What is the impact of regulatory changes on patent filings and approvals for allogenic CAR-T cell therapies?
• How are partnerships, collaborations, mergers, and acquisitions among the key industry players shaping the industry dynamics?

Reasons to Purchase this Report

The allogenic CAR-T cell patent landscape report offers comprehensive insights into the rapidly evolving patent landscape of a critical cancer treatment technology. The report provides an in-depth analysis of landscape size, key drivers, and future growth projections, along with detailed segmentation by target indications and antigens. It highlights technological advancements, improvements in manufacturing processes, and strategies to overcome immune rejection. Additionally, the report covers regional patent activities and profiles leading companies in the sector. Understanding these dynamics will help stakeholders make informed decisions and identify opportunities for innovation and collaboration in this burgeoning field.


This product will be delivered within 5-7 business days.